ATP. a pioneer in life sciences venture capital, is developing the next generation of transformative biotechnology companies.
We create science-based companies starting with assets at various stages: from working with scientists on pre-IP ideas, to spinouts from existing company pipelines.
We provide flexible capital, strategic insight, and operational resources to build sustainable, research-driven enterprises.
We invest in our companies from seed stage through IPO and beyond, and we support our management teams in strategic transactions and synergistic business combinations.
Akero Therapeutics Initiates Phase 2b HARMONY Study of Efruxifermin (EFX) for the Treatment of NASH
Gala Therapeutics Receives FDA Approval to Commence Pivotal Trial to Evaluate the RheOx™ System for Chronic Bronchitis
Chinook Receives Rare Pediatric Disease Designation from U.S. FDA for CHK-336 for Treatment of Primary Hyperoxaluria
Galaxy Medical CENTAURI PEF System to be Displayed at AF Symposium Recorded Case Presentation
ATP and Biolojic Design Launch Aulos Bioscience to Develop Highly Differentiated IL-2 Antibody Approach to Fighting Cancer
Chinook Therapeutics Announces License Agreement with Morehouse School of Medicine for Development of Therapies in Kidney Diseases Disproportionately Affecting African Americans and Underserved Communities